These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 22236410)

  • 21. [Glucagon-like peptide-1: a cardiological perspective].
    Elvekjaer M; Engstrøm T; Jensen JS; Treiman M
    Ugeskr Laeger; 2010 Oct; 172(41):2822-6. PubMed ID: 20961501
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Glucagon-like peptide-1 receptor agonists].
    Kurose T; Seino Y
    Nihon Rinsho; 2012 May; 70 Suppl 3():689-92. PubMed ID: 22768599
    [No Abstract]   [Full Text] [Related]  

  • 23. Integrating incretin-based therapy into type 2 diabetes management.
    Brunton SA
    J Fam Pract; 2013 Jun; 62(6 Suppl CME):S1-8. PubMed ID: 23828807
    [No Abstract]   [Full Text] [Related]  

  • 24. [Beyond glycemic control in type 2 diabetes. Promises and gambles of therapy with glucagon-like peptide-1 receptor agonists].
    Mannucci E
    G Ital Cardiol (Rome); 2011 Dec; 12(12 Suppl 2):3-4. PubMed ID: 22158420
    [No Abstract]   [Full Text] [Related]  

  • 25. Comparing diabetes drugs--helping clinical decisions?
    Thethi T; Fonseca V
    Lancet; 2013 Jan; 381(9861):93-4. PubMed ID: 23141811
    [No Abstract]   [Full Text] [Related]  

  • 26. Risk of bone fractures associated with glucagon-like peptide-1 receptor agonists' treatment: a meta-analysis of randomized controlled trials.
    Su B; Sheng H; Zhang M; Bu L; Yang P; Li L; Li F; Sheng C; Han Y; Qu S; Wang J
    Endocrine; 2015 Feb; 48(1):107-15. PubMed ID: 25074632
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Beyond glucose lowering: glucagon-like peptide-1 receptor agonists, body weight and the cardiovascular system.
    Vergès B; Bonnard C; Renard E
    Diabetes Metab; 2011 Dec; 37(6):477-88. PubMed ID: 21871831
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-acting glucagon-like peptide 1 receptor agonists: a review of their efficacy and tolerability.
    Garber AJ
    Diabetes Care; 2011 May; 34 Suppl 2(Suppl 2):S279-84. PubMed ID: 21525469
    [No Abstract]   [Full Text] [Related]  

  • 29. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes.
    Drucker DJ; Nauck MA
    Lancet; 2006 Nov; 368(9548):1696-705. PubMed ID: 17098089
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Liraglutide for type 2 diabetes?
    Drug Ther Bull; 2010 May; 48(5):50-3. PubMed ID: 20447980
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sustained weight loss after treatment with a glucagon-like peptide-1 receptor agonist in an obese patient with schizophrenia and type 2 diabetes.
    Ishøy PL; Knop FK; Vilsbøll T; Glenthøj BY; Ebdrup BH
    Am J Psychiatry; 2013 Jun; 170(6):681-2. PubMed ID: 23732970
    [No Abstract]   [Full Text] [Related]  

  • 32. Current treatments and strategies for type 2 diabetes: can we do better with GLP-1 receptor agonists?
    Peterson G
    Ann Med; 2012 Jun; 44(4):338-49. PubMed ID: 22530845
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Liraglutide in oral antidiabetic drug combination therapy.
    Garber AJ
    Diabetes Obes Metab; 2012 Apr; 14 Suppl 2():13-9. PubMed ID: 22405265
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Emerging GLP-1 receptor agonists.
    Lund A; Knop FK; Vilsbøll T
    Expert Opin Emerg Drugs; 2011 Dec; 16(4):607-18. PubMed ID: 21905764
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Recent advances in incretin-based therapies.
    Russell-Jones D; Gough S
    Clin Endocrinol (Oxf); 2012 Oct; 77(4):489-99. PubMed ID: 22804841
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Insulin avoidance and treatment outcomes among patients with a professional driving licence starting glucagon-like peptide 1 (GLP-1) agonists in the Association of British Clinical Diabetologists (ABCD) nationwide exenatide and liraglutide audits.
    Thong KY; Ryder RE; Cull ML; Walton C;
    Diabet Med; 2012 May; 29(5):690-2. PubMed ID: 21988449
    [No Abstract]   [Full Text] [Related]  

  • 37. Focus on incretin-based therapies: targeting the core defects of type 2 diabetes.
    Jellinger PS
    Postgrad Med; 2011 Jan; 123(1):53-65. PubMed ID: 21293084
    [TBL] [Abstract][Full Text] [Related]  

  • 38. GLP-1 receptor agonists today.
    Marre M; Penfornis A
    Diabetes Res Clin Pract; 2011 Sep; 93(3):317-27. PubMed ID: 21767888
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Liraglutide for weight loss in obese people.
    Thum T; Anker SD
    Lancet; 2010 Feb; 375(9714):551-2; author reply 552-3. PubMed ID: 20159285
    [No Abstract]   [Full Text] [Related]  

  • 40. GLP-1 receptor agonists for type 2 diabetes mellitus: recent developments and emerging agents.
    Trujillo JM; Nuffer W
    Pharmacotherapy; 2014 Nov; 34(11):1174-86. PubMed ID: 25382096
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.